2019 Medicinal Chemistry Reviews

Volume 54, Chapter 23

To Market, to Market—2018: Biologics
Catherine A. Bolger, Suzana A. Kahn, Daša Lipovšek, William Mallet, James Wieler

1. Albuvirtide (HIV-1)
2. Burosumab (X-linked hypophosphatemia)
3. Caplacizumab (acquired thrombotic thrombocytopenic purpura)
4. Cemiplimab (advanced cutaneous squamous cell carcinoma)
5. Emapalumab (primary hemophagocytic lymphohistiocytosis)
6. Erenumab (migraine)
7. Fremanezumab (migraine)
8. Galcanezumab (migraine)
9. Ibalizumab (HIV-1)
10. Inotersen (polyneuropathy of hereditary transthyretin-mediated amyloidosis)
11. Lanadelumab (hereditary angioedema)
12. Moxetumomab pasudotox (hairy cell leukemia)
13. Patisiran (polyneuropathy of hereditary transthyretin-mediated amyloidosis)
14. Ravulizumab (paroxysmal nocturnal hemoglobinuria)
15. Tagraxofusp (blastic plasmacytoid dendritic cell neoplasm)
16. Tildrakizumab (psoriasis)

To purchase a copy of this chapter, go to our secure e-commerce site.

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org